<DOC>
	<DOCNO>NCT02278211</DOCNO>
	<brief_summary>This multi-centre observational study . It make use positron emission tomography ( PET ) tracer 18F-sodium fluoride ( 18F-NaF ) marker coronary plaque vulnerability detect culprit non-culprit unstable coronary plaque patient recent myocardial infarction . The investigator perform long-term follow-up patient determine prognostic significance coronary 18F-NaF uptake</brief_summary>
	<brief_title>Prediction Recurrent Events With 18F-Fluoride</brief_title>
	<detailed_description>The investigator intend recruit 700 patient hospitalise myocardial infarction proven multivessel coronary artery disease . All patient undergo combine CT coronary angiogram ( CTCA ) PET scan use 18F-NaF tracer . Patients clinical follow-up undergoing repeat CTCA 2 year assess progression coronary disease . Clinical review patient continue study completion ( give 2 year recruitment likely last 4 year ) follow investigator continue monitor cardiovascular event via review patient electronic health record 5 year .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>1 . Patients age ≥50 year recent ( &lt; 21 day ) type 1 myocardial infarction angiographically proven multivessel coronary artery disease define least two major epicardial vessel combination either ( ) &gt; 50 % luminal stenosis , ( b ) previous revascularization ( percutaneous coronary intervention coronary artery bypass graft surgery ) . 2 . Provision inform consent prior study specific procedures 1 . Inability unwilling give inform consent 2 . Women pregnant , breastfeed childbearing potential ( woman experience menarche , premenopausal sterilise ) enrol trial 3 . Major intercurrent illness life expectancy &lt; 2 year 4 . Renal dysfunction ( estimate glomerular filtration rate ≤30 mL/min/1.73 m2 ) 5 . Contraindication iodinate contrast agent , positron emission tomography compute tomography 6 . Atrial fibrillation 7 . Previous recruitment trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>